Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 3/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 4/20 | 0.31 |
| ▸ | CNR2 | P34972 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15923385 | 0.98 | ALDH1A1 (0.35) | L3MBTL1ALDH1A1TSHRFAAHMGLL | |
| SCHEMBL15922997 | 0.98 | ALDH1A1 (0.35) | L3MBTL1ALDH1A1TSHRFAAHMGLL | |
| SCHEMBL2317331 | 0.95 | L3MBTL1 (0.31) | L3MBTL1 | |
| SCHEMBL1450946 | 0.82 | — | — | |
| SCHEMBL10544135 | 0.74 | CNR1 (0.33) | TRPV1CNR1CNR2 | |
| SCHEMBL4290581 | 0.72 | — | — | |
| SCHEMBL21866515 | 0.69 | ALDH1A1 (0.34) | L3MBTL1ALDH1A1TSHRFAAHMGLL | |
| SCHEMBL649223 | 0.67 | SPHK1 (0.41) | ALDH1A1 | |
| SCHEMBL9500161 | 0.65 | KDM4E (0.34) | — | |
| SCHEMBL6046924 | 0.62 | TNNC1 (0.55) | ALDH1A1TSHRFAAHMGLLTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9328126-B2 | Norbornenylhydrocarbylene dihydrocarbylboranes and methods of making the same | PROMERUS, LLC (US) | 2016-05-03 | — | — | US | disclosed |
| US-20150353582-A1 | NORBORNENYLHYDROCARBYLENE DIHYDROCARBYLBORANES AND METHODS OF MAKING THE SAME | PROMERUS, LLC (US) | 2015-12-10 | — | — | US | disclosed |
| WO-2014121008-A1 | NORBORNENYLHYDROCARBYLENE DIHYDROCARBYLBORANES AND METHODS OF MAKING THE SAME | PROMERUS, LLC (US) | 2014-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353582-A1 | NORBORNENYLHYDROCARBYLENE DIHYDROCARBYLBORANES AND METHODS OF MAKING THE SAME | CYP8B1, BDKRB1, CYP1B1 | L3MBTL1 378/4885ALDH1A1 253/4885MEN1 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.